Literature DB >> 9498462

In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination.

U T Hacker1, T Jelinek, S Erhardt, A Eigler, G Hartmann, H D Nothdurft, S Endres.   

Abstract

Most knowledge about the synthesis of human tumor necrosis factor (TNF)-alpha and its regulation derives from in vitro studies. The hypothesis that the syndrome of malaise, myalgia, and low fever observed after a vaccination with live attenuated yellow fever virus could be associated with increased synthesis of TNF was investigated. Plasma samples of 15 healthy subjects taken before and until day 2 (until day 11 in 5 of these subjects) after yellow fever vaccination, showed a significant increase of plasma TNF concentration on day 2 after vaccination and a second peak on day 7. Interleukin-1 receptor antagonist (IL-1ra) concentration was significantly elevated in all subjects on day 2 after vaccination. In a control group receiving non-live vaccinations, TNF and IL-1ra concentrations were unchanged. Thus, yellow fever vaccination represents a routine medical intervention that results in a reproducible increase in the plasma concentration of TNF and secondary cytokines. This may serve as a unique model for the study of the regulation of TNF synthesis in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9498462     DOI: 10.1086/517806

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1beta after live yellow fever vaccination.

Authors:  U T Hacker; S Erhardt; K Tschöp; T Jelinek; S Endres
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

2.  Levels of proinflammatory cytokines in plasma after pneumoccoccal immunization in human immunodeficiency virus type 1-infected patients.

Authors:  H Valdez; S Purvis; R Asaad; I Valerio; B E Sha; A L Landay; M M Lederman
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.

Authors:  Rex Biedenbender; Joan Bevilacqua; Anne M Gregg; Mike Watson; Gustavo Dayan
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

4.  Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?

Authors:  M A Martins; M L Silva; A P V Marciano; V Peruhype-Magalhães; S M Eloi-Santos; j G L Ribeiro; R Correa-Oliveira; A Homma; E G Kroon; A Teixeira-Carvalho; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

5.  A West Nile virus vaccine.

Authors:  Umair Afzal; Burk Jubelt
Journal:  Curr Neurol Neurosci Rep       Date:  2011-12       Impact factor: 5.081

6.  Auditory and visual hallucinations after influenza vaccine: a case report.

Authors:  Stefania Antoniazzi; Carla Carnovale; Aurelio Sessa; Marta Gentili; Marco Matacena; Maurizia Punginelli; Emilio Clementi; Sonia Radice
Journal:  Ther Adv Vaccines       Date:  2016-10-21

Review 7.  Yellow fever: a reemerging threat.

Authors:  Christina L Gardner; Kate D Ryman
Journal:  Clin Lab Med       Date:  2010-03       Impact factor: 1.935

8.  A live, attenuated recombinant West Nile virus vaccine.

Authors:  Thomas P Monath; Jian Liu; Niranjan Kanesa-Thasan; Gwendolyn A Myers; Richard Nichols; Alison Deary; Karen McCarthy; Casey Johnson; Thomas Ermak; Sunheang Shin; Juan Arroyo; Farshad Guirakhoo; Jeffrey S Kennedy; Francis A Ennis; Sharone Green; Philip Bedford
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

9.  Current Assessment of Yellow Fever and Yellow Fever Vaccine.

Authors:  Anabelle Lefeuvre; Philippe Marianneau; Vincent Deubel
Journal:  Curr Infect Dis Rep       Date:  2004-04       Impact factor: 3.725

10.  A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.

Authors:  Angela Huttner; Christophe Combescure; Stéphane Grillet; Mariëlle C Haks; Edwin Quinten; Christine Modoux; Selidji Todagbe Agnandji; Jessica Brosnahan; Julie-Anne Dayer; Ali M Harandi; Laurent Kaiser; Donata Medaglini; Tom Monath; Pascale Roux-Lombard; Peter G Kremsner; Tom H M Ottenhoff; Claire-Anne Siegrist
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.